



## Fact sheet

<b>CEO</b>	Lars Holmkvist
<b>Chairman of the Board</b>	Mats Fischier
<b>Headquarters</b>	Glostrup, Denmark
<b>R&amp;D and Production sites</b>	Glostrup, Denmark Carpinteria, CA, USA
<b>Web address</b>	<a href="http://www.dako.com">www.dako.com</a>
<b>Revenue</b>	DKK 1,913m (2010)
<b>Number of employees</b>	More than 1,000 worldwide
<b>Ownership</b>	Private equity fund EQT
<b>Area of business</b>	<p><b>Cancer Diagnostics:</b> Dako has more than 40 years of experience within pathology and has played a pioneering role in the standardization of antibodies. Dako has grown into a well-established global company with a leading position in the pathology segment of the in vitro diagnostics (IVD) industry.</p> <p><b>Retail and OEM:</b> Through Dako's Reagent Partnership Division, Dako manages and sells a comprehensive portfolio of specific proteins and high-quality reagents for flow cytometry. In addition to the retail portfolio, RP sell monoclonal and polyclonal antibodies as bulk solutions to OEM customers.</p>
<b>Products within</b>	<ul style="list-style-type: none"><li>- Immunohistochemistry (IHC)</li><li>- pharmacoDiagnostic (PharmDx™)</li><li>- Molecular Pathology</li><li>- Special Stains</li><li>- Primary Stains (H&amp;E).</li><li>- Automated instruments, software and products for diagnostic image analysis</li></ul>
<b>History</b>	Dako was founded by the Danish Medical Doctor Niels Harboe in 1966. Dako earned its reputation for innovation and quality by introducing the first conjugated antibodies for immunohistochemistry.
<b>Pharma partnerships</b>	Dako collaborates with a number of major pharmaceutical companies to develop new potential pharmacoDiagnostic (PharmDx™) products. PharmDx™ also called companion diagnostics are used to identify patients who are most likely to benefit from a specific targeted therapy.